What is epithalon?
Epithalon, also spelled epitalon, is a synthetic peptide made of four amino acids: alanine, glutamic acid, aspartic acid and glycine. It was developed at the St. Petersburg Institute of Bioregulation and Gerontology in Russia, led by Vladimir Khavinson. The team based it on the makeup of epithalamin, a peptide extract from cattle pineal glands that they had studied in animals and in older people.
Khavinson's group classes epithalon as a peptide bioregulator, a term they use for very short peptides they believe help regulate gene activity in specific tissues. That idea has had little testing outside their research program. Epithalon is the best known of these compounds outside Russia, largely because of its link to telomeres and aging.
How does epithalon work?
Telomeres are protective caps on the ends of chromosomes that shorten each time most cells divide. Telomerase is the enzyme that can rebuild them. In studies published in the early 2000s, Khavinson's group reported that epithalon activated telomerase and lengthened telomeres in cultured human cells, letting them divide past their usual limit. The group also proposes that short peptides like epithalon enter the cell nucleus and bind DNA to change gene activity. That remains a hypothesis, and how epithalon acts in a living body is not well established.
What has research looked at?
- Telomeres in cells
- Khavinson's group reported telomerase activation and longer telomeres in human cell cultures. An independent cell study published in 2025 also reported longer telomeres, in normal cells and in two breast cancer cell lines.
- Lifespan in animals
- Studies in fruit flies, mice and rats from the same research network reported longer average lifespan and, in some strains, fewer tumors. Other labs have not widely repeated these results.
- Melatonin and the pineal gland
- In older monkeys and in small human studies, the group reported that epithalon or epithalamin restored a more youthful daily melatonin pattern.
- Older adults
- Long-term Russian studies of older people given epithalamin, the pineal extract, reported lower mortality and better health measures. They did not meet modern trial standards and used the extract rather than epithalon itself.
The amount of published work on epithalon looks large, but nearly all of it comes from Khavinson and close collaborators, much of it in Russian journals. Independent replication is scarce, and there are no large randomized human trials. Claims that it slows aging in people go well beyond the evidence.
Side effects and cautions
There is no well-designed human safety data for epithalon. Khavinson's group has reported few side effects, but their studies were not built to detect rare or long-term harm. The main open question is cancer. Most cancers rely on telomerase or another telomere-lengthening pathway to keep dividing, so a compound reported to lengthen telomeres raises a theoretical concern, even though some animal studies reported fewer tumors. Anyone with a cancer history should talk to a qualified clinician.
- Cancer risk is unknown
- A 2025 lab study reported that it lengthened telomeres in two breast cancer cell lines, apparently through a pathway called ALT, which is a reason for caution.
- Informally reported effects
- Injection site irritation, headache, tiredness and sleep changes are described informally, but these come from anecdote rather than trials.
- Pregnancy and young people
- There is no safety data in pregnancy, breastfeeding or children.
Further reading
This page summarizes the research in plain words. To read the studies yourself:
- Published studies on Epithalon PubMed, US National Library of Medicine
